ScreenerHero

KOD Kodiak Sciences Inc.

NAS · US · Healthcare · Biotechnology · kodiak.com
91.40USD+0.36%Mkt Cap: 5.72B $P/E: —

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.72B USD
Enterprise Value5.72B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-229.97M USD
Revenue/Share—
Last Price91.40 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-26.88
PEG—
EV/EBITDA-24.76
EV/Revenue—
P/S—
P/B94.80
EPS (TTM)-4.19
EPS (Forward)-3.44
52W Range
10.9486% of range104.00
52W High104.00 USD
52W Low10.94 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-146.12%
ROA-65.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-136.01M USD
CapEx (TTM)506.00K USD
FCF Margin—
FCF Yield-1.02%
Net Debt-73.15M USD
Net Debt/EBITDA0.32
Balance Sheet
Debt/Equity0.38
Current Ratio2.49
Quick Ratio2.39
Book Value/Sh0.97 USD
Cash/Share2.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)116.67 USD
Upside (mean)+27.6%
Target Range96.00 USD – 145.00 USD
96.00+27.6% to mean145.00
# Analysts6
Ownership
Shares Out.62.85M
Float36.86M
Insiders5.16%
Institutions105.55%
Short Interest
Short Ratio17.8d
Short % Float26.87%
Short % Out.16.98%
Shares Short10.67M
Short (prev mo.)10.30M
Technical
SMA 5044.70 (+104.5%)
SMA 20035.98 (+154.1%)
Beta2.04
S&P 52W Chg16.45%
Avg Vol (30d)2.62M
Avg Vol (10d)6.49M
Technical Indicators
RSI (14)79.2
MACD15.4588
MACD Signal10.5846
MACD Hist.+4.8743
BB Upper117.74 USD
BB Middle57.14 USD
BB Lower-3.4693 USD
BB Width212.14%
ATR (14)7.295 USD
Vol Ratio (20d)0.36x